Landscapes / Targets
Bcl-2
15 drugs act on Bcl-2, in 69 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs15
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Approved | Nov 2026soonPhase 1/2 trial completes | |||
| Next date | Nov 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma and 34 more | ||||
| Open drug page | |||||
BCL-2 inhibitor |
AbbVie · Public ABBV |
Approved | Nov 2026soonPhase 2 trial completes | ||
| How it works | Blocks BCL-2 | ||||
| Next date | Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Multiple Myeloma, Acute Myeloid Leukemia and 10 more | ||||
| Open drug page | |||||
— |
Approved in China | Dec 2026Phase 2 trial completes | |||
| Next date | Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Chronic Lymphocytic Leukemia, CLL/SLL and 11 more | ||||
| Open drug page | |||||
— |
AbbVie · Public ABBV |
Phase 3 | 31 Dec 2026Phase 1 trial completes | ||
| Next date | 31 Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | Myelofibrosis (MF), Myeloproliferative Neoplasm | ||||
| Open drug page | |||||
Mesutoclaxnot checked |
— |
Phase 3 | Dec 2027Phase 2 trial completes | ||
| Next date | Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Relapsed or Refractory Mantle Cell Lymphoma (MCL), Hematological Malignancies and 6 more | ||||
| Open drug page | |||||
— |
Phase 3 | Dec 2030Phase 3 trial completes | |||
| Next date | Dec 2030 · Phase 3 trial completes | ||||
| Also tested for | Myeloid Malignancy, Small Lymphocytic Lymppho and 1 more | ||||
| Open drug page | |||||
— |
Phase 2 | 1 Dec 2026soonPhase 2 trial completes | |||
| Next date | 1 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Safety, Antitumor Activity and 1 more | ||||
| Open drug page | |||||
— |
Phase 2 | 30 Mar 2028Phase 2 trial completes | |||
| Next date | 30 Mar 2028 · Phase 2 trial completes | ||||
| Also tested for | Acute Myeloid Leukemia, Myelodysplastic Syndromes and 7 more | ||||
| Open drug page | |||||
— |
AbbVie · Public ABBV |
Phase 1/2 | Dec 2030Phase 1/2 trial completes | ||
| Next date | Dec 2030 · Phase 1/2 trial completes | ||||
| Also tested for | Relapsed/Refractory Multiple Myeloma, Chronic Lymphocytic Leukemia and 2 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | — | |||
| Also tested for | Hematologic Malignancy, Non Hodgkin Lymphoma and 3 more | ||||
| Open drug page | |||||
— |
Phase 1 | Dec 2026Phase 1 trial completes | |||
| Next date | Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | CLL / SLL, CLL (Chronic Lymphocytic Leukemia) and 4 more | ||||
| Open drug page | |||||
— |
Phase 1 | 31 Dec 2026Phase 1 trial completes | |||
| Next date | 31 Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | Non Hodgkin Lymphoma, Richter Transformation and 11 more | ||||
| Open drug page | |||||
— |
Phase 1 | Mar 2027Phase 1 trial completes | |||
| Next date | Mar 2027 · Phase 1 trial completes | ||||
| Also tested for | Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL) and 10 more | ||||
| Open drug page | |||||
— |
Phase 1 | 30 Jul 2027Phase 1 trial completes | |||
| Next date | 30 Jul 2027 · Phase 1 trial completes | ||||
| Also tested for | Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer and 1 more | ||||
| Open drug page | |||||
— |
Phase 1 | 7 Aug 2028Phase 1 trial completes | |||
| Next date | 7 Aug 2028 · Phase 1 trial completes | ||||
| Also tested for | B-Cell Lymphoma, Acute Myeloid Leukemia and 2 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 14 of 15 drugs. The other 1 is marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026